Business Wire

MA-VERACODE

14.2.2024 13:51:34 CET | Business Wire | Press release

Share
Veracode Reveals Critical Security Debt Can Be Reduced by 75% With Speed of Remediation

Veracode, a global leader in intelligent software security, today unveils its annual State of Software Security (SoSS) 2024 report, shedding light on the pressing issue of security debt in applications. Security debt, defined for this report as flaws that remain unfixed for longer than a year, exists in 42 percent of applications and 71 percent of organizations. Worryingly, 46 percent of organizations have persistent, high-severity flaws that constitute ‘critical’ security debt, putting businesses at serious risk in terms of impact on confidentiality, integrity, and availability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240214981363/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

State of Software Security 2024 Figure 25: Effect of flaw remediation speed on prevalence of security debt (Graphic: Business Wire)

According to the report, approximately 63 percent of applications have flaws in first-party code, while 70 percent contain flaws in third-party code imported via third-party libraries. This highlights the importance of testing both types throughout the software development life cycle. Remediation rates also vary by flaw type—fixing third-party flaws takes 50 percent longer, with half the known flaws fixed after 11 months, compared to seven months for first-party flaws.

There is good news, however: high-severity security flaws in applications have decreased by half since 2016, indicating progress in software security practices and that speed of remediation has a material impact on critical security debt.

SoSS 2024 reveals development teams that fix flaws the fastest reduce critical security debt by 75 percent—from 22.4 percent of applications to just over five percent. Moreover, these fast-acting teams are four times less likely to let critical security debt materialize in their applications in the first place.

Chris Eng, Chief Research Officer at Veracode, said, "While we continue to see improvements in the security landscape, these findings are a wake-up call for organizations to address their security debt head-on. By prioritizing flaw remediation, focusing on third-party code security, and adopting efficient development practices, organizations can significantly reduce their security debt and enhance the overall state of software security across the board."

Addressing AI and the Software Supply Chain

In an era where AI (artificial intelligence) is rapidly revolutionizing software development, the report highlights a concerning trend. Chris said, “Despite the speed and efficiency AI brings to software development, it does not necessarily produce code that’s secure. Research has shown that 36 percent of code generated by GitHub CoPilot contains security flaws.” This proliferation of insecure code at scale poses a significant risk to organizations and the software supply chain, leading to the accumulation of security debt over time.

Risk Prioritization is Key

Veracode’s research also found remediation capacity among teams to be constrained, with only 64 percent of applications having a remediation capacity that’s sufficient to eliminate critical security debt. In fact, only two out of ten applications show an average monthly fix rate that exceeds ten percent of all security flaws. This suggests, even in cases where teams’ fix capacity is sufficient, they are not prioritizing critical flaws.

Despite this, there is hope for success. Only three percent of all flaws constitute critical security debt, and this subset represents the largest risk exposure for applications. By prioritizing that three percent, organizations can achieve maximum risk reduction with focused effort.

Chris closed, "AI also paves the way for a new frontier in software security by empowering organizations to scale remediation efforts and more easily address the long backlog of security debt, as well as new flaws that emerge. The vast majority of CWEs (Common Weakness Enumeration) with a severity rating from medium to very high can be addressed through AI-generated code edits from Veracode Fix.”

The full State of Software Security 2024 report is available to download on the Veracode website. To access the report and gain deeper insights into the findings and recommendations, visit the website. A blog outlining the key findings from the report is also available to read.

-END-

About the State of Software Security Report

The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.

About Veracode

Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240214981363/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye